References: Supraventricular Arrhythmias

Lesson Progress

0% Complete

January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;(64):e1–e76.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke . 1991;22:983–988.
Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest . 2018;154:1121–1201.
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2019;74:104–132. doi: 10.1016/j.jacc.2019.01.011
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with Nonvalvular atrial fibrillation from the RELY trial. J Thromb Haemost. 2011;9:2168–2175. doi: 10.1111/j.15387836.2011.04498.
Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–1214. [PubMed: 23991661]
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891. [PubMed:21830957]
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992. [PubMed: 21870978]
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104. [PubMed: 24251359]
Haas S, Ten Cate H, Accetta G, et al. Quality of vitamin K antagonist control and 1 year outcomes in patients with atrial fibrillation: A global perspective from the GARFIELDAF registry. PloS One . 2016;11(10):e0164076. doi: 10.1371/journal.pone.0164076.
Patel MR, Hellkamp AS, Lokhnygina Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: Analysis from the ROCKET AF trial (Rivaroxaban OnceDaily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol. 2013;61:651–658. [PubMed: 23391196]
Van Gelder IC, Hagens VE, Bosker HA, et al. The Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–1840. [PubMed:12466507]
The Atrial Fibrillation FollowUp Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–1833. [PubMed: 12466506]
Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet . 2000;356:1789–1794. [PubMed: 11117910]
Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate control versus rhythm control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690–1696. [PubMed: 12767648]
Opolski G, Torbicki A, Kosior DA, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: The results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest . 2004;126:476–486. [PubMed: 15302734]
Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667–2677. [PubMed: 18565859]
de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs rhythm control in patients with atrial fibrillation: A metaanalysis. Arch InternMed. 2005;165:258–262. [PubMed: 15710787]
Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363–1373. [PubMed: 20231232]
Baker WL, Sobieraj DM, DiDomenico RJ. Influence of digoxin on mortality in patients with atrial fibrillation: Overview of systematic reviews.
Pharmacotherapy . 2021;41(4):394–404. doi: 10.1002/phar.251033544894.
Lopes RD, Rordorf R, De Ferrari GM, et al. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol. 2018;71:1063–1074.
Caldeira D, Costa J, Ferreira JJ, Lip GYH, Pinto FJ. Nonvitamin K oral anticoagulants in the cardioversion of patients with atrial fibrillation:Systemic review and metaanalysis. Clin Res Cardiol. 2015;104:582–590
Lafuente LaFuente C, Mouly S, LongásTejero MA, et al. Antiarrhythmic medications for maintaining sinus rhythm after cardioversion of atrial fibrillation. Arch Intern Med. 2006;166:719–728
Fang MC, Stafford RS, Ruskin JN, et al. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med.2004;164:55–60.
Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation . 2012;125:381–389. doi: 10.1161/circulationaha.111.019927
AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: An AFFIRM substudy of the first antiarrhythmic medication. J Am Coll Cardiol. 2003;42:20–29
Hasbrouck M, Nguyen TT. Acute management of atrial fibrillation in congestive heart failure with reduced ejection fraction in the emergency department. Am J Emerg Med. 2022 Apr 6;58:39-42.
Patel MR, Mahaffey KW, Garg J, Pan et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10. PMID: 21830957.
Connolly SJ, Ezekowitz MD, Yusuf S, et alL; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877. PMID: 19717844.
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92;
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104.
Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation . 2016;133:e506–e574.
Porter MJ, Morton JB, Denman R, et al. Influence of age and gender on the mechanism of supraventricular tachycardia. Heart Rhythm . 2004;1:393–396. [
Sung RJ, Lauer MR, Chun H. Atrioventricular node reentry: Current concepts and new perspectives. Pacing Clin Electrophysiol. 1994;17:1413–1430.
DiMarco JP, Miles W, Akhtar M, et al. Adenosine for paroxysmal supraventricular tachycardia: Dose ranging and comparison with verapamil. Assessment in placebo controlled, multicenter trials. Ann Intern Med. 1990;1113:104–110.
Jackman WM, Wang Z, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff Parkinson White syndrome) by radiofrequency current. N Engl J Med. 1991;324:1605–1611.
Glatter KA, Cheng J, Dorostkar P et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Circulation. 1999;99(8):1034‐40.
McDowell M, Mokszycki R, Greenberg A et al. Single‐syringe administration of diluted adenosine. Acad Emerg Med. 2020;27(1):61‐63.
Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ, Campbell WB, Haines DE, Kuck KH, Lerman BB, Miller DD, Shaeffer CW, Stevenson WG, Tomaselli GF, Antman EM, Smith SC Jr, Alpert JS, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Hiratzka LF, Hunt SA, Jacobs AK, Russell RO Jr, Priori SG, Blanc JJ, Budaj A, Burgos EF, Cowie M, Deckers JW, Garcia MA, Klein WW, Lekakis J, Lindahl B, Mazzotta G, Morais JC, Oto A, Smiseth O, Trappe HJ; European Society of Cardiology Committee, NASPE-Heart Rhythm Society. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias–executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol. 2003 Oct 15;42(8):1493-531. doi: 10.1016/j.jacc.2003.08.013. PMID: 14563598.
Link MS, et al. Part 6: electrical therapies: automated external defibrillators, defibrillation, cardioversion, and pacing. Circulation. 2010 Nov 2;122(18 Suppl 3):S706-19
Hafeez Y, Armstrong TJ. Atrioventricular Nodal Reentry Tachycardia. 2023 Feb 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 29763111.
Mahtani AU, Nair DG. Supraventricular Tachycardia. Med Clin North Am. 2019 Sep;103(5):863-879. doi: 10.1016/j.mcna.2019.05.007. PMID: 31378331.
Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: adult Advanced Cardiac Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2015: 132: S444‐64.
Flyer JN1, Zuckerman WA1, Richmond ME1, Anderson BR1, Mendelsberg TG1, McAllister JM1, Liberman L1, Addonizio LJ1, Silver ES2. Prospective Study of Adenosine on Atrioventricular Nodal Conduction in Pediatric and Young Adult Patients After Heart Transplantation. Circulation. 2017 Jun 20;135(25):2485-2493. PMID: 28450351
Alabed S, Sabouni A, Providencia R, Atallah E, Qintar M, Chico TJ. Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia. Cochrane Database Syst Rev. 2017;10:CD005154. Doi: 10.1002/14651858.CD005154.pub
Gupta A, Naik A, Vora A, Lokhandwala Y. Comparison of efficacy of intravenous diltiazem and esmolol in terminating supraventricular tachycardia. J Assoc Physicians India. 1999;47:969–972.
Neumar RW, Otto CW, Link MS et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122(18 Suppl 3):S729‐67.

Emergency Medicine: Cardiology 213

Participants 396

References: Supraventricular Arrhythmias